

EFFECTIVENESS OF THE RECOMMENDED THERAPEUTIC PROTOCOLS IN *HELICOBACTER PYLORI* ERADICATION: A SINGLE CENTRE TEN-YEAR EXPERIENCE

Sandra Saraiva

UEG Week Copenhagen 2023

Poster

Stomach & H. Pylori

October 15, 2023

A prospective cohort study of 523 patients found bismuth-based and concomitant quadruple therapies achieved significantly higher *Helicobacter pylori* eradication rates than sequential or triple therapy, with noncompliance, previous eradication attempts, and lack of statin use independently associated with treatment failure.

KEY POINTS

- Eradication rates in treatment-naïve patients were highest with concomitant quadruple therapy (92.5%) and bismuth-based quadruple therapy (91.1%), compared to sequential therapy (82%) and triple therapy (76.1%).
- Combined eradication rate for bismuth-based and concomitant quadruple regimens was 91.9% versus 78.3% for sequential and triple therapies ($p < 0.001$), though quadruple therapies had higher adverse event rates (16.2% versus 4.4%).
- Multivariate analysis identified three independent predictors of treatment failure: noncompliance (OR 80.1), previous eradication therapy (OR 2.6), and lack of concomitant statin use (OR 2.7).
- Overall compliance was high at 97.1% with no significant differences between regimens, and the study included consecutive patients treated between 2013 and 2022 primarily for dyspepsia.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/b37e78c4-743b-11ee-ac5b-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.